The exterior of Johnson and Johnson's subsidiary Janssen Vaccines in Leiden, Netherlands March 9, 2021. REUTERS/Piroschka van de Wouw
The company and law firm names shown above are generated automatically based on the text of the article. We are improving this feature as we continue to test and develop in beta. We welcome feedback, which you can provide using the feedback tab on the right of the page.
(Reuters) - Johnson & Johnson's Janssen Pharmaceuticals must face claims that it fraudulently obtained a patent to extend its monopoly on its prostate cancer drug Zytiga, a federal judge has ruled, in one of several unusual False Claims Act lawsuits brought by a patent attorney over drugmakers' use of patents.
U.S. District Judge Kevin McNulty on Friday denied Janssen's motion to dismiss the lawsuit by Zachary Silbersher, rejecting the company's argument that his whistleblowing under the False Claims Act was based on already public information.
"We believe the court's well-reasoned decision is an important precedent holding pharmaceutical companies accountable for charging monopoly prices for medicine based on fraudulently acquired patents," Nicomedes Herrera of Herrera Kennedy, a lawyer for Silbersher, said in an email.
Janssen did not...
PHOENIX — A Peoria man pleaded guilty April 8 to filing false claims for refund, taking home $1.8 million in tax credits related to COVID-19, authorities said. Leslie Victor Gentry, 54, prepared a...